Abstract 1442P
Background
We previously reported that intratumoral HER2 heterogeneity was associated with limited treatment efficacy to trastuzumab-based chemotherapy for HER2 positive advanced gastric cancer (AGC). In this study, we investigated the mechanism of resistance associated with intratumoral HER2 heterogeneity through ctDNA analysis.
Methods
We enrolled tissue-confirmed HER2 positive AGC patients who received chemotherapy with anti-HER2 and anti-PD-1 dual-targeted therapy from a phase Ib clinical trial. We compared clinical characteristics, gene alterations that obtained by ctDNA panel (Guardant 360®), and clinical outcomes of chemotherapy with the dual targeted therapy according to the intratumor HER2 heterogeneity status.
Results
Somatic alterations in ctDNA were detected in 20 of 21 (95.2%) patients. Among them, HER2-homo was observed in 8 of 20 patients (40.0%). AGC patients with HER2-homo tended to have a higher proportion of immunohistochemistry 3+ than those with HER2-hetero (100% vs 58.3%, P = 0.055), and the ERBB2 copy number variant (CNV) detection rate in HER2-homo tended to be higher than those in HER2-hetero (87.5% vs 41.7%, P = 0.07). In addition, ctDNA ERBB2 copy number in HER2-homo was significantly higher than those in HER2-hetero (4.5 copies vs 2.51 copies, P = 0.045). In contrast, the proportion of single nucleotide variant (SNV)s or CNVs associated with the cell cycle tended to be lower in HER2 homo than in HER2 hetero (25% vs 75%, P = 0.065). Regarding clinical outcomes of chemotherapy with HER2 and PD-1 dual targeted therapy, both median progression free survival (PFS) and overall survival (OS) in the HER2-homo was tended to be longer than that in the HER2-hetero (PFS: 20.8 months [95% CI] 8.4–NA] vs. 11.3 months [95% CI 5.5–16.3]; hazard ratio (HR) 0.36; 95% CI 0.11–1.24; P = 0.1, OS: NA [95% CI 14–NA] vs. 21.0 months [95% CI 10–NA]; HR 0.36; 95% CI 0.06–1.98; P = 0.24).
Conclusions
Intra-tumor HER2 heterogeneity, classified to homogenous or heterogenous, may be a useful biomarker associated with distinct tumor biology to predict the clinical efficacy of anti-HER2 and anti- PD-1 dual targeted therapy in patients with HER2 positive AGC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Ono Pharmaceutical Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1525P - Nab-paclitaxel/gemcitabine with or without epigenetic targeting followed by consolidating immune targeting with durvalumab and lenalidomide in patients with advanced pancreatic ductal adenocarcinoma: Results from the SEPION/AIO-PAK-0118 phase I/II study
Presenter: Jens Siveke
Session: Poster session 18
1527P - GnP vs mFOLFIRINOX or S-IROX in metastatic pancreatic cancer: 1-year follow-up updated data from the GENERATE (JCOG1611)
Presenter: Satoshi Kobayashi
Session: Poster session 18
1528P - TCOG T5221 trial: A phase II randomized study of gemcitabine and nab-paclitaxel in combination with S- 1/LV (GASL) or oxaliplatin (GAP) as first-line treatment for metastatic pancreatic cancer
Presenter: Yung-yeh Su
Session: Poster session 18
1531TiP - TWINPEAK phase I/II study, PT886 a bispecific antibody targeting claudin 18.2 and CD47 in combination with chemotherapy and/or pembrolizumab in gastric/GEJ-carcinomas or PDAC
Presenter: Michael Overman
Session: Poster session 18
1532TiP - Zolbetuximab with gemcitabine + nab-paclitaxel (GN) in first-line treatment of Claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase II, open-label, randomized study
Presenter: Wungki Park
Session: Poster session 18
1533TiP - A multicenter, open-label phase II study to evaluate the efficacy and safety of pimicotinib (CSF-1R inhibitor) in combination with chemotherapy with or without toripalimab in patients (pts) with advanced pancreatic ductal adenocarcinoma (aPDAC)
Presenter: Xiaofei Zhang
Session: Poster session 18
1534TiP - Valproic acid combinEd with Simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic Pancreatic Adenocarcinoma patients-VESPA trial
Presenter: Alfredo Budillon
Session: Poster session 18